个人中心 - 老虎社区

Ychia1761

IP属地：未知

帖子 · 106帖子 · 106
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Ychia1761Ychia1761
  ·2021-10-27
  继续加油
  小鹏汽车难飞上天，和太阳肩并肩
  三年实现飞行汽车量产，可行性有多大？这已经是小鹏发布的第六版飞行汽车了，种种迹象表明，小鹏对飞行汽车是动了真感情。在飞行汽车这个日渐火热的赛道，小鹏不是唯一的参与者，吉利、腾讯等企业也早有布局。
  小鹏汽车难飞上天，和太阳肩并肩
  1,545 评论
  点赞
  分享
  举报
- Ychia1761Ychia1761
  ·2021-10-16
  [微笑]
  EV stocks rose in morning trading
  EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%. Tes
  EV stocks rose in morning trading
  3,107 评论
  3
  分享
  举报
- Ychia1761Ychia1761
  ·2021-07-14
  When done ?
  BRIEF-Corsair Partnering Corporation Announces Pricing Of IPO
  June 30 (Reuters) - Corsair Partnering Corp : * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFE
  BRIEF-Corsair Partnering Corporation Announces Pricing Of IPO
  1,082 评论
  1
  分享
  举报
- Ychia1761Ychia1761
  ·2021-07-05
  自己打压自己国家的公司？[惊讶]
  非常抱歉，此主贴已删除
  2,548 1
  4
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-29
  Invest any ev //@wooikuang: Ok
  非常抱歉，此主贴已删除
  1,309 评论
  点赞
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-29
  Looking for it...
  非常抱歉，此主贴已删除
  2,430 评论
  1
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-19
  Other Factory quality control no confident[惊讶]
  非常抱歉，此主贴已删除
  3,558 评论
  5
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-19
  Profitable company. Good
  Adobe Getting Lift From Economic Reopening Post-Pandemic
  Software giant Adobe is benefiting as the economy reopens following the Covid-19 pandemic, a senior executive says.
  Adobe Getting Lift From Economic Reopening Post-Pandemic
  1,672 评论
  6
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-15
  Dividend stocks ..
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  It was "better late than never" for Novavax, Inc.NVAX, as the biopharma finally got around to announ
  Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up
  1,255 评论
  点赞
  分享
  举报
- Ychia1761Ychia1761
  ·2021-06-14
  Probably... still growth.
  非常抱歉，此主贴已删除
  1,229 评论
  点赞
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3572055614914535","uuid":"3572055614914535","gmtCreate":1608989752929,"gmtModify":1612237927616,"name":"Ychia1761","pinyin":"ychia1761","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":264,"tweetSize":106,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.59%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":852246219,"gmtCreate":1635287694450,"gmtModify":1635287694650,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"继续加油","listText":"继续加油","text":"继续加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852246219","repostId":"1124399064","repostType":4,"repost":{"id":"1124399064","kind":"news","pubTimestamp":1635259327,"share":"https://www.laohu8.com/m/news/1124399064?lang=&edition=full","pubTime":"2021-10-26 22:42","market":"us","language":"zh","title":"小鹏汽车难飞上天，和太阳肩并肩","url":"https://stock-news.laohu8.com/highlight/detail?id=1124399064","media":"新熵","summary":"三年实现飞行汽车量产，可行性有多大？\n\n这已经是小鹏发布的第六版飞行汽车了，种种迹象表明，小鹏对飞行汽车是动了真感情。\n在飞行汽车这个日渐火热的赛道，小鹏不是唯一的参与者，吉利、腾讯等企业也早有布局。","content":"<blockquote>\n 三年实现飞行汽车量产，可行性有多大？\n</blockquote>\n<p>这已经是小鹏发布的第六版飞行汽车了，种种迹象表明，小鹏对飞行汽车是动了真感情。</p>\n<p>在飞行汽车这个日渐火热的赛道，小鹏不是唯一的参与者，吉利、腾讯等企业也早有布局。乐观派认为电动汽车的发展为电动航空奠定了技术基础，2040年飞行车市场规模将超过一万亿美元。那么三年内量产的可能性有多大呢？</p>\n<p>关于飞行汽车，同济大学航空与动力学院教授沈海军在接受第一财经采访时曾表示，从技术角度讲量产没有任何问题，能不能量产主要取决于产品的成熟度以及相关配套的法律法规。一旦在使用过程中出现安全问题，将会直接导致产品无法推广，这不是某个企业靠一己行为就能做到的。</p>\n<p>就连平日里行事大胆的马斯克也不看好飞行汽车，他曾公开表示：“如果漫天都是这东西在飞，那飞行汽车就会像飓风一样吵，而且肯定会有汽车从上面掉下来。”</p>\n<p>另外，我国目前对飞行汽车的监管尚处于起步阶段，整片通行飞行的区域较少。在监管尚未完善情况下，飞行汽车商业化场景非常有限。</p>\n<p>飞行汽车已经发展了100多年，但至今无法实现量产。短短三五年，小鹏汇天能做到吗？</p>\n<p><b>超级补能与智能驾驶</b></p>\n<p>小鹏汽车1024科技日，有现实版的智能驾驶和超级补能，也有科幻版的飞行汽车。</p>\n<p>论汽车的智能化，小鹏可以争一争业界第一。特斯拉虽然也不错，但由于导航不太适合中国国情，语音交互也有点弱，这就减掉了不少分。所以关于智能化方面就不再多说，只说本次活动的几个重点：</p>\n<p>1、相比两年前在PPT上谈智能驾驶，这一次小鹏底气更足了；</p>\n<p>2、销量上来了——9月销量已破万，2021年内累计已交付56404辆新车，而且高速NGP（导航辅助驾驶）和停车场记忆泊车功能的激活率达到59.29%，积累了大量数据；</p>\n<p>3、目前的NGP功能只能在高速和城市快速路上使用，但很快（预计2022上半年）会普及到城市普通道路。不过要基于带激光雷达的车型，例如P5。目测P7的小改款也会加上激光雷达。</p>\n<p>4、对于“泊车+城市+高速”的全场景智能驾驶，何小鹏表示：“核心要看落地的质量，比较好地落地我认为到后年，很好的落地我认为到2025年、2026、2027年，完全的落地可能要2030年以后。”</p>\n<p>关于超级补能方面的信息有：</p>\n<p>1、截至目前小鹏自建超充站共有439座，未来将推进车端、桩端、站端的全面技术升级；</p>\n<p>2、怎么升级？车端，使用碳化硅技术支持800V高压充电，充电5分钟，续航200公里；</p>\n<p>3、桩端，将铺设480kW高压超充桩。考虑到女性使用，会采用超细线缆，提线时不会太费力；</p>\n<p>4、这么大的电流，电网无法承受怎么办？自研的储能技术来了，削峰填谷，减轻电网压力。</p>\n<p>接下来看一下本次科技日中噱头十足的东西：飞行汽车。</p>\n<p><b>飞行汽车是噱头还是妄想</b></p>\n<p>小鹏做飞行汽车已经多年，产品也迭代了N个版本，今年放出的是第六代设计稿：</p>\n<p><img src=\"https://static.tigerbbs.com/21d90f94f1b18f8dff882424d366a5e5\" tg-width=\"1080\" tg-height=\"584\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>小鹏汇天第六代飞行汽车设计稿</p>\n<p>笔者第一次注意到小鹏要造飞行汽车的时候，第一直觉就是：</p>\n<p>噱头大于实用；</p>\n<p>用来品牌增值；</p>\n<p>创始人的执念。</p>\n<p>飞行汽车并不是什么新奇物种，几十年以来，执意造飞行汽车的公司已经白骨累累。</p>\n<p>早在80年代，波音公司就曾计划打造一款廉价的飞行汽车，动力系统由一个燃气涡轮发动机和直升机传动轴构成，但在烧掉600万美元后夭折。</p>\n<p>空客也设计过pop up飞行汽车，但始终处于概念阶段：</p>\n<p>同样迟迟不能量产上市的还有阿斯顿·马丁发布的“VOLANTE VISION CONCEPT”：</p>\n<p>现阶段市面上最接近现实的只有两家公司：一家是Terrafugia（中文名“太力”），另一家是PAL-V。</p>\n<p>太力是美国的一家公司（2017年被吉利收购），推出过两代产品，分别是Transition和TF-X。第二代Transition技术比较成熟，已被美国航空主管部门允许商业化使用（消费者需要飞行执照才能开）。样子如下图：</p>\n<p>个头不小，看起来十足像一个小型客机，但座位却只有两个。本来计划今年量产，预售价28万美元，折合人民币约180万。但由于诸多原因，这款飞行汽车已经接近“胎死腹中”。</p>\n<p>另一家荷兰制造商PAL-V制造的是一种三轮摩托+自转旋翼构型飞行汽车，售价约60万美元。目前已经通过欧洲道路通行考核，可以挂牌上路。但由于还没有通过欧洲航空安全局的航空认证，还不能升空：</p>\n<p>PAL-V制造的飞行汽车Liberty</p>\n<p>综合起来看，这些飞行汽车难以成功的原因无非以下几点：</p>\n<p>1、政策管制问题；</p>\n<p>2、成本高昂、结构复杂，没有继承汽车和飞机的优点，反而继承了缺点；</p>\n<p>3、机翼庞大笨重，对场地的要求太高。</p>\n<p>从原理上讲，只要人类的飞行技术还依赖于空气，那么无论是固定翼还是旋翼，升力的产生都依赖于机翼相对于空气的运动，要使气体的升力足以支撑一两吨重的汽车，必然会造成大范围的气体扰流。</p>\n<p>请自行脑补一下直升机下面的风有多大，噪音有多大。</p>\n<p><b>这就注定了，在新的飞行原理出现之前，飞行汽车不太可能大规模进入社区。</b></p>\n<p>即使在居民区附近开辟出一片起降场地，其成本也不是多数民众能承受的，更不用说扩量以后复杂的空中调度问题。</p>\n<p>其终局，可能在相当长一段时间内，都是小众有钱人的玩具。</p>\n<p><b>小鹏是认真的吗？</b></p>\n<p>关键是，我们想到的这些问题，小鹏不可能没想到。</p>\n<p><b>从种种迹象看，小鹏是真的“动了情”。</b></p>\n<p>为了尽可能地轻量化，它的车身采用了碳纤维、航空铝材、镁合金及特殊玻璃等材料，电池采用高能量密度的电芯，在电驱和机械结构上也做了集成化设计。这一套操作下来，相比小鹏P7的重量，减重幅度接近50%——小鹏P7重约2吨，这个飞行汽车减重到一吨。</p>\n<p>为了尽可能的操作简单、免去飞行驾照，小鹏在交互方面大幅精简，飞行时只需单杆操作，并在自动辅助驾驶方面做了不少功课。</p>\n<p>为了保证安全，做了多道保护，还配备了整机降落伞。售价控制在100万以内。</p>\n<p>在演讲的最后，何小鹏掷地有声地说道：“我们的目标是，在2024年实现飞行汽车的量产。”</p>\n<p>最终能不能成功？谁也不知道。连何小鹏自己都说：既然探索，一定会有失败，如果不会失败就不叫探索了。</p>\n<p>倒是从这件事上，可以看到小鹏的文化基因。何小鹏作为创业者的特质，也和马斯克有几分相像。</p>\n<p>要比“不靠谱”，马斯克的哪个项目都让人感觉不靠谱。从早期要造世界上最酷的电动车，到后来的星链计划、脑机接口，都有点科幻。但他倒是真的在一步步推进。</p>\n<p>程序员出身的何小鹏，也早就实现财务自由。37岁时他将自己创立的UC手机浏览器以43.5亿美元卖给了阿里，本可以从此逍遥后半生，但不安分的天性使他二次创业，进入了汽车圏。这种出发点决定了他不会像大多数公司一样把盈利放在第一位：</p>\n<p>“我想做一些不一样的产品，想去折腾自己后面的时间，因为我也不安分，包括儿子出世，一下情感上打动了，我就觉得那让小朋友将来能听一些爸爸的故事。</p>\n<p>“对我来说，我觉得对于越来越多的创业者都想做更好的东西，而不是想做更赚钱的东西……我一九八几年第一次坐在一台车上，那时候的车跟现在的车也差不了太远。为什么30年来车都没有巨大的变化？我们如果再去造一个也没有巨大变化的车子，只追求它的定位、它的价格差异，那我创业干什么？创业就是做不一样的事情，就像我们每个人要做不一样的人。”</p>\n<p>所以小鹏汽车在创新上，有一些让人难以理解的固执：</p>\n<p>曾经他想让P7上的玻璃可以像波音787飞机的玻璃一样能够调亮度、调透光率，不想晒太阳的时候可以把玻璃调到最暗。</p>\n<p>但样品出来后，没有达到想要的效果，而是变成一个雾气状态下不均匀的深灰，最终放弃了这一想法。何小鹏还讲过一个例子：</p>\n<p>“2019年时，我想在P7上做一个灯。这个灯是可以在线升级的，我希望有个功能是，当你的女朋友来的时候，它会显示一种特别欢迎的灯语。这里涉及到的能力有，首先，你要识别这里有个人，并且是你女朋友，其次，这个灯最好可以你自己编程。技术人员就和我说做不到，供应商不配合，以及成本、时间周期等等，反正讲了无数理由，就是我不干，或是干了没有什么意义。这种时候我就生气，这东西你只要花力气，3个月干不好可以9个月对不对，30万干不了可以60万对不对？我一般先讲一下道理和逻辑，他已经听懂了，但还是想讲难度——我要做的是结果，不是难度，再不行我就换人。”</p>\n<p>在当今一派“赚钱焦虑症”的环境下，能有这样的“固执”属实不多。</p>\n<p>或许正因为此，做飞行汽车的小鹏汇天在10月19日顺利完成了A轮融资，拿到了超过5亿美元的资金，投前估值超10亿美元。</p>\n<p>投资机构的名单中，IDG资本、红杉中国、钟鼎资本、GGV纪源资本、高瓴等知名创投机构统统在列。</p>\n<p>看来，无论小鹏汽车最终能不能够飞上天，这种认真的劲头已经打动了不少人——的确，这个时代太需要来一些突破想象力的东西了。</p>","source":"lsy1602476715181","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>小鹏汽车难飞上天，和太阳肩并肩</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n小鹏汽车难飞上天，和太阳肩并肩\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-26 22:42 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s/4t-GtZJWNeA_kB1fBGFR9w><strong>新熵</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>三年实现飞行汽车量产，可行性有多大？\n\n这已经是小鹏发布的第六版飞行汽车了，种种迹象表明，小鹏对飞行汽车是动了真感情。\n在飞行汽车这个日渐火热的赛道，小鹏不是唯一的参与者，吉利、腾讯等企业也早有布局。乐观派认为电动汽车的发展为电动航空奠定了技术基础，2040年飞行车市场规模将超过一万亿美元。那么三年内量产的可能性有多大呢？\n关于飞行汽车，同济大学航空与动力学院教授沈海军在接受第一财经采访时曾表示，...</p>\n\n<a href=\"https://mp.weixin.qq.com/s/4t-GtZJWNeA_kB1fBGFR9w\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/78138efa6a1e5d4e76e51f7f75be90ea","relate_stocks":{"XPEV":"小鹏汽车","09868":"小鹏汽车-W"},"source_url":"https://mp.weixin.qq.com/s/4t-GtZJWNeA_kB1fBGFR9w","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124399064","content_text":"三年实现飞行汽车量产，可行性有多大？\n\n这已经是小鹏发布的第六版飞行汽车了，种种迹象表明，小鹏对飞行汽车是动了真感情。\n在飞行汽车这个日渐火热的赛道，小鹏不是唯一的参与者，吉利、腾讯等企业也早有布局。乐观派认为电动汽车的发展为电动航空奠定了技术基础，2040年飞行车市场规模将超过一万亿美元。那么三年内量产的可能性有多大呢？\n关于飞行汽车，同济大学航空与动力学院教授沈海军在接受第一财经采访时曾表示，从技术角度讲量产没有任何问题，能不能量产主要取决于产品的成熟度以及相关配套的法律法规。一旦在使用过程中出现安全问题，将会直接导致产品无法推广，这不是某个企业靠一己行为就能做到的。\n就连平日里行事大胆的马斯克也不看好飞行汽车，他曾公开表示：“如果漫天都是这东西在飞，那飞行汽车就会像飓风一样吵，而且肯定会有汽车从上面掉下来。”\n另外，我国目前对飞行汽车的监管尚处于起步阶段，整片通行飞行的区域较少。在监管尚未完善情况下，飞行汽车商业化场景非常有限。\n飞行汽车已经发展了100多年，但至今无法实现量产。短短三五年，小鹏汇天能做到吗？\n超级补能与智能驾驶\n小鹏汽车1024科技日，有现实版的智能驾驶和超级补能，也有科幻版的飞行汽车。\n论汽车的智能化，小鹏可以争一争业界第一。特斯拉虽然也不错，但由于导航不太适合中国国情，语音交互也有点弱，这就减掉了不少分。所以关于智能化方面就不再多说，只说本次活动的几个重点：\n1、相比两年前在PPT上谈智能驾驶，这一次小鹏底气更足了；\n2、销量上来了——9月销量已破万，2021年内累计已交付56404辆新车，而且高速NGP（导航辅助驾驶）和停车场记忆泊车功能的激活率达到59.29%，积累了大量数据；\n3、目前的NGP功能只能在高速和城市快速路上使用，但很快（预计2022上半年）会普及到城市普通道路。不过要基于带激光雷达的车型，例如P5。目测P7的小改款也会加上激光雷达。\n4、对于“泊车+城市+高速”的全场景智能驾驶，何小鹏表示：“核心要看落地的质量，比较好地落地我认为到后年，很好的落地我认为到2025年、2026、2027年，完全的落地可能要2030年以后。”\n关于超级补能方面的信息有：\n1、截至目前小鹏自建超充站共有439座，未来将推进车端、桩端、站端的全面技术升级；\n2、怎么升级？车端，使用碳化硅技术支持800V高压充电，充电5分钟，续航200公里；\n3、桩端，将铺设480kW高压超充桩。考虑到女性使用，会采用超细线缆，提线时不会太费力；\n4、这么大的电流，电网无法承受怎么办？自研的储能技术来了，削峰填谷，减轻电网压力。\n接下来看一下本次科技日中噱头十足的东西：飞行汽车。\n飞行汽车是噱头还是妄想\n小鹏做飞行汽车已经多年，产品也迭代了N个版本，今年放出的是第六代设计稿：\n\n小鹏汇天第六代飞行汽车设计稿\n笔者第一次注意到小鹏要造飞行汽车的时候，第一直觉就是：\n噱头大于实用；\n用来品牌增值；\n创始人的执念。\n飞行汽车并不是什么新奇物种，几十年以来，执意造飞行汽车的公司已经白骨累累。\n早在80年代，波音公司就曾计划打造一款廉价的飞行汽车，动力系统由一个燃气涡轮发动机和直升机传动轴构成，但在烧掉600万美元后夭折。\n空客也设计过pop up飞行汽车，但始终处于概念阶段：\n同样迟迟不能量产上市的还有阿斯顿·马丁发布的“VOLANTE VISION CONCEPT”：\n现阶段市面上最接近现实的只有两家公司：一家是Terrafugia（中文名“太力”），另一家是PAL-V。\n太力是美国的一家公司（2017年被吉利收购），推出过两代产品，分别是Transition和TF-X。第二代Transition技术比较成熟，已被美国航空主管部门允许商业化使用（消费者需要飞行执照才能开）。样子如下图：\n个头不小，看起来十足像一个小型客机，但座位却只有两个。本来计划今年量产，预售价28万美元，折合人民币约180万。但由于诸多原因，这款飞行汽车已经接近“胎死腹中”。\n另一家荷兰制造商PAL-V制造的是一种三轮摩托+自转旋翼构型飞行汽车，售价约60万美元。目前已经通过欧洲道路通行考核，可以挂牌上路。但由于还没有通过欧洲航空安全局的航空认证，还不能升空：\nPAL-V制造的飞行汽车Liberty\n综合起来看，这些飞行汽车难以成功的原因无非以下几点：\n1、政策管制问题；\n2、成本高昂、结构复杂，没有继承汽车和飞机的优点，反而继承了缺点；\n3、机翼庞大笨重，对场地的要求太高。\n从原理上讲，只要人类的飞行技术还依赖于空气，那么无论是固定翼还是旋翼，升力的产生都依赖于机翼相对于空气的运动，要使气体的升力足以支撑一两吨重的汽车，必然会造成大范围的气体扰流。\n请自行脑补一下直升机下面的风有多大，噪音有多大。\n这就注定了，在新的飞行原理出现之前，飞行汽车不太可能大规模进入社区。\n即使在居民区附近开辟出一片起降场地，其成本也不是多数民众能承受的，更不用说扩量以后复杂的空中调度问题。\n其终局，可能在相当长一段时间内，都是小众有钱人的玩具。\n小鹏是认真的吗？\n关键是，我们想到的这些问题，小鹏不可能没想到。\n从种种迹象看，小鹏是真的“动了情”。\n为了尽可能地轻量化，它的车身采用了碳纤维、航空铝材、镁合金及特殊玻璃等材料，电池采用高能量密度的电芯，在电驱和机械结构上也做了集成化设计。这一套操作下来，相比小鹏P7的重量，减重幅度接近50%——小鹏P7重约2吨，这个飞行汽车减重到一吨。\n为了尽可能的操作简单、免去飞行驾照，小鹏在交互方面大幅精简，飞行时只需单杆操作，并在自动辅助驾驶方面做了不少功课。\n为了保证安全，做了多道保护，还配备了整机降落伞。售价控制在100万以内。\n在演讲的最后，何小鹏掷地有声地说道：“我们的目标是，在2024年实现飞行汽车的量产。”\n最终能不能成功？谁也不知道。连何小鹏自己都说：既然探索，一定会有失败，如果不会失败就不叫探索了。\n倒是从这件事上，可以看到小鹏的文化基因。何小鹏作为创业者的特质，也和马斯克有几分相像。\n要比“不靠谱”，马斯克的哪个项目都让人感觉不靠谱。从早期要造世界上最酷的电动车，到后来的星链计划、脑机接口，都有点科幻。但他倒是真的在一步步推进。\n程序员出身的何小鹏，也早就实现财务自由。37岁时他将自己创立的UC手机浏览器以43.5亿美元卖给了阿里，本可以从此逍遥后半生，但不安分的天性使他二次创业，进入了汽车圏。这种出发点决定了他不会像大多数公司一样把盈利放在第一位：\n“我想做一些不一样的产品，想去折腾自己后面的时间，因为我也不安分，包括儿子出世，一下情感上打动了，我就觉得那让小朋友将来能听一些爸爸的故事。\n“对我来说，我觉得对于越来越多的创业者都想做更好的东西，而不是想做更赚钱的东西……我一九八几年第一次坐在一台车上，那时候的车跟现在的车也差不了太远。为什么30年来车都没有巨大的变化？我们如果再去造一个也没有巨大变化的车子，只追求它的定位、它的价格差异，那我创业干什么？创业就是做不一样的事情，就像我们每个人要做不一样的人。”\n所以小鹏汽车在创新上，有一些让人难以理解的固执：\n曾经他想让P7上的玻璃可以像波音787飞机的玻璃一样能够调亮度、调透光率，不想晒太阳的时候可以把玻璃调到最暗。\n但样品出来后，没有达到想要的效果，而是变成一个雾气状态下不均匀的深灰，最终放弃了这一想法。何小鹏还讲过一个例子：\n“2019年时，我想在P7上做一个灯。这个灯是可以在线升级的，我希望有个功能是，当你的女朋友来的时候，它会显示一种特别欢迎的灯语。这里涉及到的能力有，首先，你要识别这里有个人，并且是你女朋友，其次，这个灯最好可以你自己编程。技术人员就和我说做不到，供应商不配合，以及成本、时间周期等等，反正讲了无数理由，就是我不干，或是干了没有什么意义。这种时候我就生气，这东西你只要花力气，3个月干不好可以9个月对不对，30万干不了可以60万对不对？我一般先讲一下道理和逻辑，他已经听懂了，但还是想讲难度——我要做的是结果，不是难度，再不行我就换人。”\n在当今一派“赚钱焦虑症”的环境下，能有这样的“固执”属实不多。\n或许正因为此，做飞行汽车的小鹏汇天在10月19日顺利完成了A轮融资，拿到了超过5亿美元的资金，投前估值超10亿美元。\n投资机构的名单中，IDG资本、红杉中国、钟鼎资本、GGV纪源资本、高瓴等知名创投机构统统在列。\n看来，无论小鹏汽车最终能不能够飞上天，这种认真的劲头已经打动了不少人——的确，这个时代太需要来一些突破想象力的东西了。","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":1545,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824219666,"gmtCreate":1634314267052,"gmtModify":1634314267232,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"[微笑]","listText":"[微笑]","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/824219666","repostId":"1188641122","repostType":4,"repost":{"id":"1188641122","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634305460,"share":"https://www.laohu8.com/m/news/1188641122?lang=&edition=full","pubTime":"2021-10-15 21:44","market":"us","language":"en","title":"EV stocks rose in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1188641122","media":"Tiger Newspress","summary":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.\n\nTes","content":"<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/718cbd03e21f15e45c2574be4e4017b5\" tg-width=\"401\" tg-height=\"242\" referrerpolicy=\"no-referrer\"></p>\n<p>Tesla&nbsp;edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker&nbsp;to $950 from $850.</p>\n<p>Analyst&nbsp;Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.</p>\n<p>Following further analysis of third-quarter data and various sources of information on the&nbsp;soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.</p>\n<p>In addition,&nbsp;Houchois said&nbsp;sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"</p>\n<p>Chinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.</p>\n<p>XPeng&nbsp;published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.</p>\n<p>Solid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks rose in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks rose in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-15 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto&nbsp;climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/718cbd03e21f15e45c2574be4e4017b5\" tg-width=\"401\" tg-height=\"242\" referrerpolicy=\"no-referrer\"></p>\n<p>Tesla&nbsp;edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker&nbsp;to $950 from $850.</p>\n<p>Analyst&nbsp;Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.</p>\n<p>Following further analysis of third-quarter data and various sources of information on the&nbsp;soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.</p>\n<p>In addition,&nbsp;Houchois said&nbsp;sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"</p>\n<p>Chinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.</p>\n<p>XPeng&nbsp;published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.</p>\n<p>Solid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","TSLA":"特斯拉","NIO":"蔚来","XPEV":"小鹏汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188641122","content_text":"EV stocks rose in morning trading.Tesla,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.\n\nTesla edged higher Friday after a Jefferies analyst raised his price target on the electric vehicle maker to $950 from $850.\nAnalyst Philippe Houchois, who affirmed a buy rating on Tesla, boosted his price target after raising his estimates of earnings before interest and taxes 7% to 9% for 2022-2023, according to the Fly.\nFollowing further analysis of third-quarter data and various sources of information on the soon-to-be launched Berlin facility, the analyst said that he saw a higher capacity ramp and sustained demand.\nIn addition, Houchois said sees little evidence of legacy automakers closing the gap as Tesla continues to challenge them \"at multiple levels.\"\nChinese electric vehicle maker Nio Inc said it would double the capacity of its Hefei plant to 240,000 vehicles a year, up from 120,000 units.\nXPeng published its first ESG report on Thursday. ESG is short for environmental, social and governance and companies publish ESG reports—sometimes called sustainability reports or impact reports—to tell stakeholders how their operations are impacting communities they serve.\nSolid ESG reports are one less thing for investors to worry about. That’s good news for XPeng.","news_type":1,"symbols_score_info":{"LI":0.9,"NIO":0.9,"TSLA":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":3107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":144198009,"gmtCreate":1626270803301,"gmtModify":1633928433218,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"When done ?","listText":"When done ?","text":"When done ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/144198009","repostId":"2148484521","repostType":2,"repost":{"id":"2148484521","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625098710,"share":"https://www.laohu8.com/m/news/2148484521?lang=&edition=full","pubTime":"2021-07-01 08:18","market":"us","language":"en","title":"BRIEF-Corsair Partnering Corporation Announces Pricing Of IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2148484521","media":"Reuters","summary":"June 30 (Reuters) - Corsair Partnering Corp   :   * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFE","content":"<html><body><p>June 30 (Reuters) - Corsair Partnering Corp   :</p><p>   * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING</p><p>   * ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 25,000,000 UNITS AT $10.00 PER UNIT</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Corsair Partnering Corporation Announces Pricing Of IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Corsair Partnering Corporation Announces Pricing Of IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-01 08:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 30 (Reuters) - Corsair Partnering Corp   :</p><p>   * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING</p><p>   * ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 25,000,000 UNITS AT $10.00 PER UNIT</p><p> Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORS.U":"Corsair Partnering Corp."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148484521","content_text":"June 30 (Reuters) - Corsair Partnering Corp   :   * ORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING   * ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 25,000,000 UNITS AT $10.00 PER UNIT Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"CORS.U":1}},"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155410167,"gmtCreate":1625448376559,"gmtModify":1633940619433,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"自己打压自己国家的公司？[惊讶]&nbsp;","listText":"自己打压自己国家的公司？[惊讶]&nbsp;","text":"自己打压自己国家的公司？[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/155410167","repostId":"1169840279","repostType":4,"isVote":1,"tweetType":1,"viewCount":2548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":159002195,"gmtCreate":1624929999717,"gmtModify":1633946879822,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Invest any ev&nbsp;//<a href=\"https://laohu8.com/U/3570512829067659\">@wooikuang</a>: Ok","listText":"Invest any ev&nbsp;//<a href=\"https://laohu8.com/U/3570512829067659\">@wooikuang</a>: Ok","text":"Invest any ev //@wooikuang: Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/159002195","repostId":"2124875875","repostType":4,"isVote":1,"tweetType":1,"viewCount":1309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150777952,"gmtCreate":1624929738376,"gmtModify":1633946885253,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Looking for it...","listText":"Looking for it...","text":"Looking for it...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150777952","repostId":"2146835880","repostType":4,"isVote":1,"tweetType":1,"viewCount":2430,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162898027,"gmtCreate":1624054339969,"gmtModify":1634023583336,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Other Factory quality control no confident[惊讶]&nbsp;","listText":"Other Factory quality control no confident[惊讶]&nbsp;","text":"Other Factory quality control no confident[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162898027","repostId":"2144771068","repostType":4,"isVote":1,"tweetType":1,"viewCount":3558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":162893025,"gmtCreate":1624054162867,"gmtModify":1634023584892,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Profitable company. Good&nbsp;","listText":"Profitable company. Good&nbsp;","text":"Profitable company. Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162893025","repostId":"2144774740","repostType":4,"repost":{"id":"2144774740","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1624030096,"share":"https://www.laohu8.com/m/news/2144774740?lang=&edition=full","pubTime":"2021-06-18 23:28","market":"us","language":"en","title":"Adobe Getting Lift From Economic Reopening Post-Pandemic","url":"https://stock-news.laohu8.com/highlight/detail?id=2144774740","media":"Investors","summary":"Software giant Adobe is benefiting as the economy reopens following the Covid-19 pandemic, a senior executive says.","content":"<p>Software giant <b><a href=\"https://laohu8.com/S/ADBE\">Adobe</a></b> is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.</p>\n<p>The maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.</p>\n<p>The San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.</p>\n<p>For the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.</p>\n<h2>ADBE Stock Rises After Earnings Report</h2>\n<p>In morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.</p>\n<p>\"All three of our businesses — Creative Cloud, Document Cloud and <a href=\"https://laohu8.com/S/EXP.AU\">Experience</a> Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"</p>\n<p>That momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.</p>\n<p>\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"</p>\n<p>The reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.</p>\n<h2>Analysts Raise Price Targets On Adobe Stock</h2>\n<p>At least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.</p>\n<p>Mizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.</p>\n<p>\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"</p>\n<p>On June 11, ADBE stock broke out of a 40-week&nbsp;consolidation period&nbsp;at a&nbsp;buy point&nbsp;of 536.98, according to&nbsp;IBD MarketSmith charts.</p>\n<p>However, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adobe Getting Lift From Economic Reopening Post-Pandemic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdobe Getting Lift From Economic Reopening Post-Pandemic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-06-18 23:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Software giant <b><a href=\"https://laohu8.com/S/ADBE\">Adobe</a></b> is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.</p>\n<p>The maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.</p>\n<p>The San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.</p>\n<p>For the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.</p>\n<h2>ADBE Stock Rises After Earnings Report</h2>\n<p>In morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.</p>\n<p>\"All three of our businesses — Creative Cloud, Document Cloud and <a href=\"https://laohu8.com/S/EXP.AU\">Experience</a> Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"</p>\n<p>That momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.</p>\n<p>\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"</p>\n<p>The reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.</p>\n<h2>Analysts Raise Price Targets On Adobe Stock</h2>\n<p>At least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.</p>\n<p>Mizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.</p>\n<p>\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"</p>\n<p>On June 11, ADBE stock broke out of a 40-week&nbsp;consolidation period&nbsp;at a&nbsp;buy point&nbsp;of 536.98, according to&nbsp;IBD MarketSmith charts.</p>\n<p>However, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ADBE":"Adobe"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144774740","content_text":"Software giant Adobe is benefiting as the economy reopens as the Covid-19 pandemic wanes, a senior executive says. The company's beat-and-raise quarterly report provided proof of that. ADBE stock jumped on Friday.\nThe maker of digital media and marketing software late Thursday reported fiscal second-quarter earnings that easily topped expectations. Adobe also guided above views for the current quarter.\nThe San Jose, Calif.-based company earned an adjusted $3.03 a share on sales of $3.84 billion in the quarter ended June 4. On a year-over-year basis, Adobe earnings rose 24% while sales climbed 23%.\nFor the current quarter, Adobe expects to earn an adjusted $3 a share, up 17%, on sales of $3.88 billion, up 20%.\nADBE Stock Rises After Earnings Report\nIn morning trading on the stock market today, ADBE stock advanced 2.2%, near 563.35. Earlier in the session, ADBE stock notched a record high 570.\n\"All three of our businesses — Creative Cloud, Document Cloud and Experience Cloud — just killed it this quarter with excellent performance,\" Chief Financial Officer John Murphy told Investor's Business Daily. \"Content creation and customer experience engagement in personalized ways are resonating across all of our businesses. And it's really driving the momentum and acceleration in the business.\"\nThat momentum will continue in the company's seasonally weaker fiscal third quarter, Murphy said. The current quarter includes the summer months of June, July and August.\n\"The macroeconomic stability is giving a lot of enterprises confidence to invest again,\" Murphy said. \"Companies are prioritizing digital transformation.\"\nThe reopening of the economy and return to offices after the pandemic should provide a tailwind for Adobe's business, he said.\nAnalysts Raise Price Targets On Adobe Stock\nAt least 15 Wall Street analysts raised their price targets on ADBE stock after the earnings report.\nMizuho Securities analyst Gregg Moskowitz reiterated his buy rating on ADBE stock and upped his price target to 640 from 600.\n\"Adobe's expansive portfolio of software solutions has made it the gold standard in content creation, consumption, and collaboration,\" Moskowitz said in a note to clients. \"Adobe is very well positioned to benefit from digital transformation with its comprehensive end-to-end offering that differentiates it from competitors.\"\nOn June 11, ADBE stock broke out of a 40-week consolidation period at a buy point of 536.98, according to IBD MarketSmith charts.\nHowever, IBD Leaderboard analysis offered investors an earlier buy point of 525.54 from a cup base within the larger consolidation pattern.","news_type":1,"symbols_score_info":{"ADBE":0.9}},"isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187727551,"gmtCreate":1623765041173,"gmtModify":1634028690408,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Dividend stocks ..","listText":"Dividend stocks ..","text":"Dividend stocks ..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187727551","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185020552,"gmtCreate":1623627714676,"gmtModify":1634031112556,"author":{"id":"3572055614914535","authorId":"3572055614914535","name":"Ychia1761","avatar":"https://static.tigerbbs.com/86fc697237da30bd6102449174caafb8","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572055614914535","authorIdStr":"3572055614914535"},"themes":[],"htmlText":"Probably... still growth.","listText":"Probably... still growth.","text":"Probably... still growth.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185020552","repostId":"2142713203","repostType":4,"isVote":1,"tweetType":1,"viewCount":1229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}